CHARLOTTESVILLE, Va., Nov. 7, 2012 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, will present data on its transformational liver surrogate systems at The Liver Meeting 2012, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, Massachusetts, on November 9-13. AASLD is the world's leading organization of scientists and healthcare professionals committed to preventing and curing liver disease.
On Monday, November 12, from 8:00 a.m. to 5:00 p.m., HemoShear will present its innovative in vitro hepatic steatosis system. Visitors at the conference can view Abstract 1438 Development of an In-vitro Model of Hepatic Steatosis Using Rat Hepatocytes Under Controlled Hemodynamics in a Diabetic Milieu, Authored by HemoShear scientists Tye G. Deering, Joshua T. Thomas, Brett R. Blackman, Brian R. Wamhoff, and Ajit Dash.
For more information on the content of HemoShear's abstract, interested parties may visit the AASLD website at http://www.aasld.org/lm2012/2012/abstracts/Pages/default.aspx.
About HemoShear LLC
By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.
SOURCE HemoShear LLC